Also, given the role of PD-L1/PD-1 in blockade therapies, the expression has to be characterized to compensate for heterogeneity in the tumor microenvironment and measurement techniques/technologies for the effective applications of immune checkpoint inhibitors. This evidence concerns the gene CD274 and neoplasm.